25 results
Thumbnail

D2.430 - Two cases of acquired angioedema: one with splenic lymphoma and the other with Waldenström’s macroglobulinemia

Thumbnail

D2.431 - Association of serum IgE levels and atopic status with cancer in the general population

Thumbnail

D2.433 - AllergoOncology: Immunocompetent 3D and Skin Organoid Models of Melanoma to Investigate Tumour-Immune Interactions and Immunotherapies

Thumbnail

D2.434 - AllergoOncology: Novel crusade for Basophil Activation Test

Thumbnail

D2.432 - Blood morphology in health & cancer: comparative, preliminary study on 783 patients

Thumbnail

D3.260 - Bempedoic acid allergy in a patient with hypercholesterolemia

Thumbnail

- D3.262 - Bempedoic acid allergy in a statin-intolerant patient with hypercholesterolemia

Thumbnail

D3.252 - Azithromycin and Mycoplasma pneumonia: an unusual Stevens-Johnson syndrome case

Thumbnail

D3.256 - Is an Early-Type Hypersensitivity Reaction Possible with Both Peroral and Parenteral Anticoagulant Drugs? A Successful 2-Day Peroral Desensitization Protocol to Rivaroxaban

Thumbnail

D3.257 - Two cases of propofol anaphylaxis revealed by provocation test

Thumbnail

D3.258 - Probable drug- induced Enterocolitis Syndrome (DIES) caused by Amoxicillin

Thumbnail

D3.259 - KOLLIPHOR : An excipient to be futher explored

Thumbnail

D3.263 - Rare case of anaphylaxis to lidocaine in skin testing during perioperative anaphylaxis investigation

Thumbnail

D3.264 - Pioneering study evaluating the Basophil Activation Test (BAT), PENFAST and skin sensitization to penicillin in patients with gestational syphilis

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes